Chlorthalidone氯噻酮,77-36-1

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Chlorthalidone

CAS No. : 77-36-1

MCE 国际站：Chlorthalidone

产品活性：Chlorthalidone 是一种噻嗪类利尿剂，有潜力用于高血压的研究。

研究领域：Others

作用靶点：Others

In Vivo: Chlorthalidone is a thiazide-like diuretic. After oral intake, peak serum concentrations are achieved in 2-6 hours. The half-life of Chlorthalidone is approximately 42 (range 29-55) hours, reaching 45-60 hours after long-term dosing. However, interindividual variability in the half-life of Chlorthalidone is wide. Chlorthalidone is excreted unchanged by the kidneys. The natriuretic effect of Chlorthalidone is maximal at 18 hours and lasts more than 48 hours. Comparing different doses of Chlorthalidone, it has been observed that 25 mg daily is nearly as effective as higher doses, but with less risk of hypokalemia. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. The effectiveness of Chlorthalidone or magnesium hydroxide is examined in the prevention of recurrent calcium oxalate kidney calculi. In a double-blind random allocation design daily dosages of 25 or 50 mg. Chlorthalidone, 650 or 1,300 mg. magnesium hydroxide, or an identical placebo are administered. All groups showed significantly decreased calculous events compared to the pretreatment rates. During the trial 56.1 per cent fewer calculi than predicted developed in the placebo group (p less than 0.01), whereas the groups receiving low and high dosage magnesium hydroxide showed 73.9 and 62.3 per cent fewer calculi, respectively (p less than 0.001 and less than 0.01, respectively). Chlorthalidone treatment results in a 90.1 per cent decrease from predicted rates and both dosages yielded similar results. When the treatments are compared Chlorthalidone is significantly better than the placebo or magnesium hydroxide (p less than 0.01). The large decreases in calculous events seen when placebo or ineffective therapy is given underscore the positive treatment bias that occurs when historical controls are used and they demonstrate the need for proper experimental design.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Digitonin  |  5-Ph-IAA  |  FLAG peptide  |  Tocofersolan  |  Monocrotaline  |  Lactate sodium  |  TCEP hydrochloride  |  3X FLAG peptide  |  DPPH  |  Pertussis Toxin  |  Pronase E (Activity ≥ 7000 U/g)  |  O-Propargyl-Puromycin  |  NMDI14  |  Phytohemagglutinin  |  MYLS22  |  Hyaluronidase  |  Biotinyl tyramide  |  Kifunensine  |  Human IgG1 kappa, Isotype Control  |  4-Azido-L-phenylalanine  |  6-Aminonicotinamide  |  Ammonium tetrathiomolybdate(VI)  |  OVA Peptide(257-264) TFA  |  Alkyne-phenol  |  Lauryl maltose neopentyl glycol  |  SHIN1  |  CHAPS  |  Cytosporone B

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds